Mariana Oncology closed a $175m series B venture capital round to fund its first clinical trial, for MC-339 in small-cell lung cancer, as well as its manufacturing and pipeline-building activities.

Successful Phase III data for UCB’s C5 inhibitor zilucoplan adds to a similarly positive Phase III readout for its rozanolixizumab in December, but details are lacking. UCB is the only company with two mechanisms for MG.

Argenx's efgartigimod could very soon become the first anti-FcRn agent to get approval for generalized myasthenia gravis but UCB’s rival therapy rozanolixizumab for the rare muscular disease is nearly ready to be filed with regulators.

MK-0616 – administered orally – reduced LDL cholesterol in patients in two early clinical trials presented at the American Heart Association Scientific Sessions.